Skip to main content
    N

    Novo Nordisk A/S (NVO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $41.60
    -0.03 (-0.07%)

    Market Cap: $183.52B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novo Nordisk A/S (NVO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in DKK.

    Novo Nordisk A/S reported revenue of DKK 309.06B for the fiscal year ended Dec 31, 2025, up 6.4% from the year before. That year, net income was DKK 102.43B with a net margin of 33.1%, operating cash flow was DKK 119.10B and free cash flow was DKK 28.99B. The quarter ended Sep 30, 2026 had revenue of DKK 79.19B and net income of DKK 16.74B.

    Revenue and Margins

    The operating margin was 41.3% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from DKK 111.78B, a compound annual rate of 12.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025309.06B+6.4%81.0%41.3%33.1%
    Dec 2024290.40B+25.0%84.7%44.2%34.8%
    Dec 2023232.26B+31.3%84.6%44.2%36.0%
    Dec 2022176.95B+25.7%83.9%42.3%31.4%
    Dec 2021140.80B+10.9%83.2%41.7%33.9%
    Dec 2020126.95B+4.0%83.5%42.6%33.2%
    Dec 2019122.02B+9.1%83.5%43.0%31.9%
    Dec 2018111.83B+0.1%84.2%42.2%34.5%
    Dec 2017111.70B-0.1%84.2%43.8%34.1%
    Dec 2016111.78BN/A84.6%43.3%33.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 1.4% from the year before. In the quarter ended Sep 2026, net income fell 16.3% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue309.06B290.40B232.26B176.95B140.80B126.95B122.02B111.83B111.70B111.78B
    Cost of revenue58.79B44.52B35.77B28.45B23.66B20.93B20.09B17.62B17.63B17.18B
    Gross profit250.28B245.88B196.50B148.51B117.14B106.01B101.93B94.21B94.06B94.60B
    Research and development52.04B48.06B32.44B24.05B17.77B15.46B14.22B14.80B14.01B14.56B
    Operating income127.66B128.34B102.57B74.81B58.64B54.13B52.48B47.25B48.97B48.43B
    Net income102.43B100.99B83.68B55.52B47.76B42.14B38.95B38.63B38.13B37.92B
    EBITDA156.73B147.94B114.63B76.80B65.39B59.27B54.43B51.63B51.95B51.06B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue79.19B78.49B96.82B79.14B74.98B76.86B78.09B85.68B71.31B68.06B65.35B65.86B
    Gross profit60.96B61.39B83.22B64.00B57.07B64.01B65.20B72.66B60.00B57.79B55.43B55.85B
    Operating income23.01B27.06B59.62B31.74B23.68B33.45B38.79B36.74B33.82B25.93B31.85B26.77B
    Net income16.74B20.99B48.56B26.89B20.01B26.50B29.03B28.23B27.30B20.05B25.41B21.96B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of DKK 130.96B exceeded cash and equivalents by 104.49B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets542.90B465.80B314.49B241.26B194.51B144.92B125.61B110.77B102.36B97.54B
    Current assets172.45B160.90B139.65B108.19B85.59B65.81B62.46B59.07B60.08B59.77B
    Cash and equivalents26.46B15.65B14.39B12.65B10.72B12.76B15.47B15.64B18.85B18.69B
    Total liabilities348.86B322.31B207.93B157.77B123.76B81.60B68.02B58.93B52.54B52.27B
    Short-term debt12.02B13.11B6.48B1.47B13.68B7.46B1.47B515.00M1.69B229.00M
    Long-term debt118.94B84.25B15.98B20.77B9.65BN/A0000
    Shareholder equity194.05B143.49B106.56B83.49B70.75B63.33B57.59B51.84B49.81B45.27B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets599.16B594.94B559.22B542.90B512.29B482.15B489.16B465.80B397.44B53.09B298.92B314.49B
    Total liabilities381.36B373.66B356.16B348.86B342.39B314.09B350.62B322.31B276.92B36.91B200.01B207.93B
    Cash and equivalents44.15B44.48B21.13B26.46B32.08B18.43B38.94B15.65B57.02B7.59B6.32B14.39B
    Shareholder equity217.80B221.28B203.06B194.05B169.90B168.07B138.54B143.49B120.52B16.17B98.91B106.56B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 24.3% of operating cash flow. Dividends came to 178.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow119.10B120.97B108.91B78.89B55.00B51.95B46.78B44.62B41.17B48.31B
    Capital expenditures90.11B51.31B38.90B14.75B7.38B22.08B11.23B12.41B8.65B8.27B
    Free cash flow28.99B69.66B70.01B64.13B47.62B29.87B35.55B32.21B32.52B40.05B
    Dividends paid51.76B44.14B31.77B25.30B21.52B20.12B19.41B19.05B18.84B23.83B
    Investing cash flow-79.16B-128.90B-43.89B-24.92B-31.61B-22.44B-11.51B-12.08B-6.57B-6.79B
    Financing cash flow-28.41B8.73B-63.16B-51.80B-25.49B-32.24B-35.48B-34.52B-35.69B-38.89B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow41.24B55.20B24.08B7.62B46.11B40.78B24.59B12.30B43.85B50.50B14.31B9.55B
    Capital expenditures13.15B12.80B12.04B43.84B15.41B16.27B14.59B16.56B12.50B13.24B9.01B16.44B
    Free cash flow28.10B42.40B12.04B-36.22B30.69B24.51B10.01B-4.26B31.35B37.27B5.30B-6.88B
    Last 12 quarters

    Frequently Asked Questions About NVO

    What is Novo Nordisk A/S's annual revenue?

    Novo Nordisk A/S reported revenue of DKK 309.06B for the fiscal year ended Dec 31, 2025.

    How fast is Novo Nordisk A/S's revenue growing?

    Revenue was up 6.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.4%.

    Is Novo Nordisk A/S profitable?

    Yes. Novo Nordisk A/S reported net income of DKK 102.43B for the fiscal year ended Dec 31, 2025, with a net margin of 33.1%.

    How much free cash flow does NVO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of DKK 119.10B minus capital expenditures of DKK 90.11B produced free cash flow of DKK 28.99B.

    How much debt does Novo Nordisk A/S have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of DKK 118.94B, short-term debt of DKK 12.02B and cash and equivalents of DKK 26.46B.